Public-registry trials using GRN-1201 + Pembrolizumab that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC | BrightPath Biotherapeutics | Metastatic NSCLC | PHASE2 | 11 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →